Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib)
Home » Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib)

GH AMEA on Social MediaCongratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib)
Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib)
Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib)
LinkedIn

Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib) in combination with trastuzumab and capecitabine for patients with metastatic HER2-positive breast cancer who have received prior anti-HER2-based regimens. Tucatinib-based treatment improved overall and progression-free survival. A new targeted therapy, another reason to test breast cancer patients for HER2.

https://lnkd.in/es6hitM

Open chat
Message us